Merge Split Categories
Terms to be merged:
ID: 269, Name: Ankylosing (Nonradiographic Axial)
Suggested merge targets:
- Spondylitis, Ankylosing (Nonradiographic Axial)
Total pieces of content: 1
ID: 239, Name: Arterial
Suggested merge targets:
- Hypertension, Pulmonary, Arterial
- Pulmonary Arterial Hypertension
Total pieces of content: 2
- NCT02382016 – A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
- NCT03078907 – A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient’s Self-reported Symptoms and Their Impacts
ID: 259, Name: Arthritis
Suggested merge targets:
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
Total pieces of content: 1
ID: 254, Name: Atopic
Suggested merge targets:
- Dermatitis, Atopic
Total pieces of content: 1
ID: 256, Name: Chronic Lymphocytic
Suggested merge targets:
- Leukemia, Chronic Lymphocytic
Total pieces of content: 1
ID: 257, Name: Colitis
Suggested merge targets:
- Colitis, Ulcerative
Total pieces of content: 1
ID: 251, Name: Depressive Disorder
Suggested merge targets:
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
Total pieces of content: 7
- NCT03434041 – A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- NCT02497287 – An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
- NCT02493868 – A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
- NCT01998958 – A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
- NCT02918318 – A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
- NCT01627782 – A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
- NCT01640080 – A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression
ID: 253, Name: Dermatitis
Suggested merge targets:
- Dermatitis, Atopic
Total pieces of content: 1
ID: 248, Name: Diabetes Mellitus
Suggested merge targets:
- Diabetes Mellitus, Type 2
Total pieces of content: 5
- NCT02139943 – A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus
- NCT03267576 – Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
- NCT01032629 – A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
- NCT02065791 – A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
- NCT02846545 – SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
ID: 171, Name: Hypertension
Suggested merge targets:
- Hypertension, Pulmonary, Arterial
- Pulmonary Arterial Hypertension
Total pieces of content: 3
- NCT02382016 – A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
- NCT03078907 – A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient’s Self-reported Symptoms and Their Impacts
- NCT00236665 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension
ID: 255, Name: Leukemia
Suggested merge targets:
- Leukemia, Chronic Lymphocytic
- Leukemia, Myeloid, Acute
Total pieces of content: 1
ID: 261, Name: Lymphoma
Suggested merge targets:
- Lymphoma, Mantle Cell/Small Lymphocytic
Total pieces of content: 1
ID: 263, Name: Major
Suggested merge targets:
- Depressive Disorder, Major
Total pieces of content: 6
- NCT02497287 – An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
- NCT02493868 – A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
- NCT01998958 – A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
- NCT02918318 – A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
- NCT01627782 – A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
- NCT01640080 – A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression
ID: 262, Name: Mantle Cell/Small Lymphocytic
Suggested merge targets:
- Lymphoma, Mantle Cell/Small Lymphocytic
Total pieces of content: 0
No content found.
ID: 180, Name: Neoplasms
Suggested merge targets:
- Neoplasms, Breast
- Neoplasms, Ovarian
- Neoplasms, Prostatic
Total pieces of content: 8
- NCT00473512 – A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy
- NCT02165397 – iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström’s Macroglobulinemia
- NCT02489318 – A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- NCT01946204 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
- NCT01009177 – A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine
- NCT01394991 – A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia
- NCT00270166 – A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy
- NCT00270127 – Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving non-Platinum-Containing Chemotherapy
ID: 237, Name: Prostatic
Suggested merge targets:
- Neoplasms, Prostatic
Total pieces of content: 3
- NCT00473512 – A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy
- NCT02489318 – A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- NCT01946204 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
ID: 238, Name: Pulmonary
Suggested merge targets:
- Hypertension, Pulmonary, Arterial
- Idiopathic Pulmonary Fibrosis
- Pulmonary Arterial Hypertension
Total pieces of content: 2
- NCT02382016 – A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
- NCT03078907 – A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient’s Self-reported Symptoms and Their Impacts
ID: 260, Name: Rheumatoid
Suggested merge targets:
- Arthritis, Rheumatoid
Total pieces of content: 1
ID: 268, Name: Spondylitis
Suggested merge targets:
- Spondylitis, Ankylosing (Nonradiographic Axial)
Total pieces of content: 1
ID: 244, Name: Systemic
Suggested merge targets:
- Scleroderma, Systemic
Total pieces of content: 1
ID: 252, Name: Treatment-Resistant
Suggested merge targets:
- Depressive Disorder, Treatment-Resistant
Total pieces of content: 1
ID: 264, Name: Type 2
Suggested merge targets:
- Diabetes Mellitus, Type 2
Total pieces of content: 2
- NCT01032629 – A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
- NCT02065791 – A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
ID: 258, Name: Ulcerative
Suggested merge targets:
- Colitis, Ulcerative
Total pieces of content: 1